Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK.
Department of Radiology, Queen Elizabeth Hospital Birmingham, Birmingham, UK.
Clin Transplant. 2018 May;32(5):e13255. doi: 10.1111/ctr.13255. Epub 2018 May 18.
Loco-regional complications of transarterial chemoembolization (TACE) may adversely affect technical aspects of the liver transplantation (LT). This study reviewed the impact of those complications on postoperative outcomes encompassing implications on graft selection.
A retrospective, propensity score matching (1:1) analysis accounting for donor and recipient confounders was performed on a dataset of patients undergoing LT for hepatocellular carcinoma. Outcomes of patients who had TACE (TACE-group) were compared with those who did not (NoTACE-group).
A total of 57 matched pairs were analyzed. TACE achieved effective tumor control (Pre-TACE vs Post-TACE; Median: 44 mm [interquartile range: 43-50] vs 17 mm [0-36]; P = .002) on imaging follow-up. TACE group had, at the hepatectomy, higher incidence of ischemia-related complications (adhesions of the necrotic tumor, cholecystitis, and/or bile duct necrosis) (40.4% vs 10.5%; P = .001). Overall major post-LT complications rate (Dindo-Clavien ≥3) were similar (P = .134). Those in the TACE group with donors after circulatory death (DCD) had 4.6% 90-day mortality and 54.3% major complication rate compared to 6.9% and 77.3% (P = .380 and P = .112, respectively).
TACE was an effective bridging procedure that may complicate LT inducing ischemic-related complications; nevertheless, it has not shown repercussions on mortality or morbidity after the procedure, even using donors after circulatory death.
经动脉化疗栓塞术(TACE)的局部区域并发症可能会对肝移植(LT)的技术方面产生不利影响。本研究回顾了这些并发症对术后结果的影响,包括对移植物选择的影响。
对接受肝细胞癌 LT 的患者数据集进行了回顾性倾向评分匹配(1:1)分析,考虑了供体和受者混杂因素。比较了接受 TACE(TACE 组)和未接受 TACE(NoTACE 组)的患者的结果。
共分析了 57 对匹配对。TACE 在影像学随访中实现了有效的肿瘤控制(Pre-TACE 与 Post-TACE;中位数:44mm[四分位距:43-50]与 17mm[0-36];P=0.002)。TACE 组在肝切除术中,缺血相关并发症(坏死肿瘤的粘连、胆囊炎和/或胆管坏死)的发生率更高(40.4%与 10.5%;P=0.001)。整体 LT 后主要并发症发生率(Dindo-Clavien ≥3)相似(P=0.134)。在 TACE 组中,使用循环死亡供体(DCD)的患者 90 天死亡率为 4.6%,主要并发症发生率为 54.3%,而对照组分别为 6.9%和 77.3%(P=0.380 和 P=0.112,分别)。
TACE 是一种有效的桥接治疗方法,可能会引起与缺血相关的并发症,从而使 LT 复杂化;然而,即使使用循环死亡供体,它也不会对手术后的死亡率或发病率产生影响。